The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway

Endocrine-Related Cancer

Volumn 15, Issue 4, 2008, Pages 965-974

  Laezza, Chiara ^a,b   Pisanti, Simona ^c   Malfitano, Anna Maria ^c   Bifulco, Maurizio ^c  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 2' F ANANDAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; CANNABINOID DERIVATIVE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL MEMBRANE; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; HUMAN; HUMAN CELL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STRESS FIBER;

ACTINS; AMIDES; ARACHIDONIC ACIDS; BLOTTING, WESTERN; BREAST NEOPLASMS; CANNABINOIDS; CELL MEMBRANE; CELL MOVEMENT; CYTOSKELETON; CYTOSOL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MEVALONIC ACID; NEOPLASM INVASIVENESS; PYRIDINES; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 58249101216     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-08-0030     Document Type: Article

References (44)

1. Adamson P, Marshall CJ, Hall A & Tilbrook PA 1992 Post-translational modifications of p21rho proteins. Journal of Biological Chemistry 267 20033-20038.
2. Van Aelst L & D'Souza-Schorey C 1997 Rho GTPases and signaling networks. Genes and Development 11 2295-2322.
3. Bifulco M & Di Marzo V 2002 The endocannabinoid system as a target for the development of new drugs for cancer therapy. Nature Medicine 8 547-550.
4. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L & Di Marzo V 2001 Control by the endogenous cannabinoid system of ras oncogene dependent tumor growth. FASEB Journal 15 2745-2747.
5. Bifulco M, Laezza C, Pisanti S & Gazzerro P 2006 Cannabinoids and cancer: pros and cons of an antitumour strategy. British Journal of Pharmacology 148 123-135.
6. Chambers AF, Groom AC & MacDonald IC 2002 Dissemination and growth of cancer cells in metastatic sites. Nature Reviews. Cancer 8 563-572.
7. Clark EA, Golub TR, Lander ES & Hynes RO 2000 Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406 532-535.
8. Collisson EA, Carranza DC, Chen IY & Kolodney MS 2002 Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. Journal of Investigative Dermatology 119 1172-1176.
9. Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, Soria J & Soria C 2001 Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22 1139-1148.
10. Etienne-Manneville S & Hall A 2002 Rho GTPases in cell biology. Nature 420 629-635.
11. Frame MC 2004 Newest findings on the oldest oncogene; how activated src does it. Journal of Cell Science 117 989-998.
12. Fritz G, Just I & Kaina B 1999 Rho GTPases are overexpressed in human tumors. International Journal of Cancer 81 682-687.
13. Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso MG, Notamicola M, Iacuzzo I, Portella G et al. 2006 Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research 312 363-373.
14. Hall A 1998 Rho GTPases and the actin cytoskeleton. Science 279 509-514.
15. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T & Konishi I 2003 Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Laboratory Investigation 83 861-870.
16. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M & Narumiya S 2000 Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Molecular Pharmacology 57 976-983.
17. Joseph J, Niggemann 13, Zaenker KS & Entschladen F 2004 Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology and Immunotherapy 53 723-728.
18. Just I, Selzer J, Wilm M, Von Eichel-Streiber C, Mann M & Aktories K 1995 Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375 500-503.
19. Kamai T, Arai K, Tsujii T, Honda M & Yoshida K 2001 Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU International 87 227-231.
20. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y & Oshima H 2003 Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clinical Cancer Research 9 2632-2641.
21. Kusama T, Mukai M, Tatsuta M, Matsumoto Y, Nakamura H & Inoue M 2003 Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clinical & Experimental Metastasis 20 561-567.
22. Kusama T, Mukai M, Tatsuta M, Nakamura H & Inoue M 2006 Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. International Journal of Oncology 29 217-223.
23. Leung T, Manser E, Tan L & Lim L 1995 A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. Journal of Biological Chemistry 270 29051-29054.
24. Mackie K & Stella N 2006 Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS Journal 28 E298-E306.
25. McTaggart SJ 2006 Isoprenylated proteins. Cellular and Molecular Life Sciences 63 255-267.
26. Muller A, Homey B, Soto H, Ge N, Carron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN et al. 2001 Involvement of chemokine receptors in breast cancer metastasis. Nature 410 50-56.
27. Narumiya S, Ishizaki T & Watanabe N 1997 Rho effectors and reorganization of actin cytoskeleton. FEBS Letters 410 69-72.
28. Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ & Campbell W13 2004 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Research 64 8826-8830.
29. Oft M, Heider KH & Beug H 1998 TGF beta signaling is necessary for carcinoma cell invasiveness and metastasis. Current Biology 8 1243-1252.
30. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M & Di Marzo V 1998 The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. PNAS 95 8375-8380.
31. De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M & Di Matzo V 2000 Suppression of nerve growth factor Trk receptor and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 118-126.
32. Pillé JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C et al. 2005 Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Molecular Therapy 11 267-274.
33. Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P & Bifulco M 2007 Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. Journal of Cellular Physiology 211 495-503.
34. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V & Bifulco M 2003 Inhibitory effects of cannabinoid CB1 receptor stimulation on tumour growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB Journal 17 1771-1773.
35. Roymans D & Slegers H 2001 Phosphatidylinositol 3-kinases in tumor progression. European Journal of Biochemistry 268 487-498.
36. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B & Meinhardt G 2004 The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance i multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104 1825-1832.
37. Seasholtz TM, Majumdar M & Brown JH 1999 Rho as a mediator of G protein-coupled receptor signaling. Molecular Pharmacology 55 949-956.
38. Sebti SM 2005 Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 4 297-300.
39. Solski PA, Helms W, Keely PJ, Su L & Der CJ 2002 RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth and Differentiation 13 363-373.
40. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J & Soria C 2001 Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its antiangiogenic effect. FEBS Letters 495 159-166.
41. Vivanco I & Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews. Cancer 7 489-501.
42. Yoshioka K, Matsumura F, Akedo H & Itoh K 1998 Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. Journal of Biological Chemistry 273 5146-5154.
43. Yoshioka K, Nakamori S & Itoh K 1999 Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Research 59 2004-2010.
44. Zhong WB, Liang YC, Wang CY, Chang TC & Lee WS 2005 Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocrine-Related Cancer 12 615-629.